Drug
Deep 6 AI Adds $17M To Advance Clinical Trial Recruitment Software
7 monthes ago | By Xconomy
Software startup Deep 6 AI has developed a system that analyzes a range of patient health records to accelerate the process of identifying candidates for clinical trial recruitment-a longstanding bottleneck in the drug development process. The Pasadena, CA-based company, founded in 2015, recently raised $17M in Series A funding to advance its software system, which aims to use artificial intelligence tools to resolve one of research's biggest challenges: enrolling patients to participate in trials. About 80 percent of clinical trials miss enrollment timelines, and nearly one-third of Phase...
Read more ...
Search by Tags
Drug Health Clinical Drugs Research National National blog main San Diego Artificial Intelligence Biotech Deep 6 AI Life SciencesWorld Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
2nd International Conference on Tissue Science and Regenerative Medicine
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck
Foghorn Therapeutics could receive up to $425 million in the development deal with Merck, its first partnership with a major biopharma. One way that a cell regulates which... Read more ...
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership
Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based... Read more ...
Data Migration: Being Prepared
Our Professional Services Written by: Alan Pham, Business Development Associate In a world where our data is crucial to our everyday lives, implementing new platforms is... Read more ...
NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep
The first drug for neurofibromatosis type 1 is available to patients following the FDA's approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection... Read more ...
VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs
Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has... Read more ...
Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing
By early September Biogen-plus the many scientists, patients, and investors following the saga of its controversial Alzheimer's drug aducanamab-should know whether the FDA... Read more ...
The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination...
The 2020 National Xconomy Awards - celebrating the best in biotech innovation and entrepreneurship - just got bigger! We're excited to announce the expansion of the 2020... Read more ...
Scientists Dive Deep Into Hidden World of Quantum States
Right: Animation of a Van Hove singularity shown approximately 1 nanometer below the surface of an oxide heterostructure made of atomically thin layers of strontium titanate... Read more ...
UFGI Publication round-up week 7/6/20
Manipulation of sensory characteristics and volatile compounds in strawberry fruit through the use of isolated wavelengths of light. Campbell SM, Sims CA, Bartoshuk LM... Read more ...
DNA Chisel, a versatile sequence optimizer
AbstractMotivationAccounting for biological and practical requirements in DNA sequence design often results in challenging optimization problems. Current software solutions are... Read more ...